anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bodily resizing illusions typically use visual and/or tactile inputs to produce a vivid experience of one's body changing size. Naturalistic auditory input (an input that reflects the natural sounds of a stimulus) has been used to increase illusory experience during the rubber hand illusion, whilst non-naturalistic auditory input can influence estimations of finger length. We aimed to use a non-naturalistic auditory input during a hand-based resizing illusion using augmented reality, to assess whether the addition of an auditory input would increase both subjective illusion strength and measures of performance-based tasks. Forty-four participants completed the following three conditions: no finger stretching, finger stretching without tactile feedback and finger stretching with tactile feedback. Half of the participants had an auditory input throughout all the conditions, whilst the other half did not. After each condition, the participants were given one of the following three performance tasks: stimulated (right) hand dot touch task, non-stimulated (left) hand dot touch task, and a ruler judgement task. Dot tasks involved participants reaching for the location of a virtual dot, whereas the ruler task concerned estimates of the participant's own finger on a ruler whilst the hand was hidden from view. After all trials, the participants completed a questionnaire capturing subjective illusion strength. The addition of auditory input increased subjective illusion strength for manipulations without tactile feedback but not those with tactile feedback. No facilitatory effects of audio were found for any performance task. We conclude that adding auditory input to illusory finger stretching increased subjective illusory experience in the absence of tactile feedback but did not affect performance-based measures.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 tyrosine kinase. Tyrosine kinase inhibitors (TKIs) have been established as standard therapies for CML. However, some CML patients experience TKI intolerance. Asciminib was approved for CML patients either intolerant or refractory to TKI therapy. We herein report a 63-year-old CML patient who underwent renal transplantation and exhibited TKI intolerance. He was switched to asciminib, which achieved a deep molecular response without exacerbation of the renal function. Our experience revealed that asciminib is effective and safe for CML patients complicated with chronic kidney disease.
The present invention relates to an immunogenic agent comprising a low dose of an antigenic component from one or more pathogens and an agent capable of increasing an amount of IL-12 in animal, and use thereof for reducing infection or improving recovery from an infection from the pathogen. The immunogenic agent preferably comprises CpG nucleic acid, IL-12 protein and/or IL-12 nucleic acid. The pathogen is preferably an intracellular pathogen comprising one or more species and strains, such as  Plasmodium  spp. The invention also relates to a pharmaceutical composition comprising the immunogenic agent. The pharmaceutical composition is preferably an immunotherapeutic composition. The immunotherapeutic composition, is preferably a vaccine capable of providing protection against or treating  Plasmodium  spp infection, the causative agent of malaria in humans.
The invention discloses a porous chitosan membrane and a preparation method and application thereof. Mixing pure chitosan or chitosan with other macromolecules, dissolving to obtain a solution, and freezing and solidifying the chitosan solution. Injecting a low-melting-point thawing coagulant into the frozen chitosan solution, wherein the thawing coagulant comprises 1-10% by mass of strong base, 1-10% by mass of inorganic salt, 50-90% by mass of an organic solvent and the balance of water. The thawing coagulator can still melt the ice crystal structure below-0 ℃, and simultaneously, chitosan macromolecules are subjected to ion crosslinking and solidification, and the space frame structure of the chitosan macromolecules is reserved, so that the porous chitosan membrane is formed. The porous chitosan membrane has uniform pore structure, good mechanical property, imbibition and moisture retention property and biocompatibility, and can be applied to facial masks, wound dressings, operation anti-adhesion membranes or cytoskeletons. The preparation method of the invention has the advantages of simple required equipment and process, high hole forming efficiency and suitability for large-scale processing.
Patients receive cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Treatment with cetuximab repeats every 4 weeks for 2 courses. Beginning in week 2 of course 1, patients undergo concurrent IMRT 5 days per week for 7 weeks. Beginning in week 4 (day 1 of course 2) patients also receive ipilimumab IV over 90 minutes once every 21 days for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may undergo surgery after completion of therapy.
INTRODUCTION: Rotavirus-associated diarrheal diseases significantly burden healthcare systems, particularly affecting infants under five years. Both Rotarix™ (RV1) and RotaTeq™ (RV5) vaccines have been effective but have distinct application schedules and limited interchangeability data. This study aims to provide evidence on the immunogenicity, reactogenicity, and safety of mixed RV1-RV5 schedules compared to their standard counterparts.
METHODS: This randomized, double-blind study evaluated the non-inferiority in terms of immunogenicity of mixed rotavirus vaccine schedules compared to standard RV1 and RV5 schedules in a cohort of 1,498 healthy infants aged 6 to 10 weeks. Participants were randomly assigned to one of seven groups receiving various combinations of RV1, and RV5. Standard RV1 and RV5 schedules served as controls of immunogenicity, reactogenicity, and safety analysis. IgA antibody levels were measured from blood samples collected before the first dose and one month after the third dose. Non-inferiority was concluded if the reduction in seroresponse rate in the mixed schemes, compared to the standard highest responding scheme, did not exceed the non-inferiority margin of -0.10. Reactogenicity traits and adverse events were monitored for 30 days after each vaccination and analyzed on the entire cohort.
RESULTS: Out of the initial cohort, 1,365 infants completed the study. Immunogenicity analysis included 1,014 infants, considering IgA antibody titers ≥20 U/mL as seropositive. Mixed vaccine schedules demonstrated non-inferiority to standard schedules, with no significant differences in immunogenic response. Safety profiles were comparable across all groups, with no increased incidence of serious adverse events or intussusception.
CONCLUSION: The study confirms that mixed rotavirus vaccine schedules are non-inferior to standard RV1 and RV5 regimens in terms of immunogenicity and safety. This finding supports the flexibility of rotavirus vaccination strategies, particularly in contexts of vaccine shortage or logistic constraints. These results contribute to the global effort to optimize rotavirus vaccination programs for broader and more effective pediatric coverage.Clinical trial registration: ClinicalTrials.gov, NCT02193061.
FIELD: medicine, hepatology. SUBSTANCE: invention relates to agents of plant origin used for treatment of viral hepatitis. Invention proposes an agent for treatment of viral hepatitis B and C comprising lectin-containing medicinal plants: maize stigmas, common balm leaves, peppermint leaves, medicinal sage leaves, feline catnip herb, narrow-leaved willow-herb herb and medicinal pot-marigold flowers taken in their ratio = 7:3:3:1:5:7:7, respectively. Agent is made as tabletted form and has additionally water-soluble, low-molecular chitosan and filling agent taken in the following ratio of components, mg per a tablet: medicinal plants, 300-320; water-soluble chitosan, 25-27; filling agent up to 500. Also, an agent has starch and carboxymethylcellulose as a filling agent. Invention proposes also a method of treatment of viral hepatitis B and C that involves administration to patient the above indicated agent in the dose 2 tablets in the morning and evening in eating for 2-4 months. Agent and method promote the enhancement of therapy efficiency due to etiotropic and pathogenetic treatment. EFFECT: enhanced effectiveness of agent and treatment. 3 cl, 2 tbl, 3 ex
This will be a prospective, randomized, double-blinded placebo controlled study. Randomization will be performed by a random numbers table. Envelopes will be sealed with the accompanying randomization group.Patients will be eligible for inclusion in the study if they have a full-thickness rotator cuff tear that has been deemed reparable by preoperative MRI. They will be included in the study if they are medically stable to undergo the surgery and consent to involvement in the study.

Patients consenting to the study will undergo arthroscopic rotator cuff repair by one of the two senior authors. The surgery will be performed as an outpatient procedure under general anesthesia. The procedure will be performed utilizing the standard techniques of the senior authors. All concomitant pathology found at the time of arthroscopy will be treated in the usual appropriate fashion. At the completion of the rotator cuff repair, patients will be randomly allocated to one of three groups. This will be done by opening a sealed envelope with the randomization allocation. The patients will either be placed into the study group, the placebo group or the control group.
PROBLEM TO BE SOLVED: To obtain the subject composition containing a cationic polymer and/or an amphoteric polymer and a specific lactam compound, and capable of retaining the conditioning effect for a long time. SOLUTION: The composition contains (A) 0.5-30wt.% of a compound of the formula [R<1> , R<2> are each H, a 1-8C alkyl, an alkenyl, an aryl, etc.; (n), (m) satisfy each the inequality: 2<=(n)+(m)<=4; etc.] and (B) 0.01-10wt.% of one or more kinds of polymers selected from a cationic polymer and an amphoteric polymer. The compound of the formula includes N-hexylpyrrolidone. The compound of the formula has a batter penetration-promoting action than those of benzyl alcohol or N-methyl or ethyl pyrrolidone which are conventional penetration-promoting agents. When hair is treated with the composition, the component A swells the hair, thereby promoting the penetration of the component B into the hair.  The composition can be used in the form of a hair pack, a hair dye, a hair treating agent, a styling agent, a permanent wave agent, a hair color, a hair-bleaching agent, a shampoo, a hair rinse, etc.
The glymphatic system plays an important role in the transportation of cerebrospinal fluid (CSF) and the clearance of metabolite waste in brain. However, current imaging modalities for studying the glymphatic system are limited. Herein, we apply NIR-II nanoprobes with non-invasive and high-contrast advantages to comprehensively explore the function of glymphatic system in mice under anesthesia and cerebral ischemia-reperfusion injury conditions. Our results show that the supplement drug dexmedetomidine (Dex) enhances CSF influx in the brain, decreases its outflow to mandibular lymph nodes, and leads to significant differences in CSF accumulation pattern in the spine compared to isoflurane (ISO) alone, while both ISO and Dex do not affect the clearance of tracer-filled CSF into blood circulation. Notably, we confirm the compromised glymphatic function after cerebral ischemia-reperfusion injury, leading to impaired glymphatic influx and reduced glymphatic efflux. This technique has great potential to elucidate the underlying mechanisms between the glymphatic system and central nervous system diseases.
A prospective follow-up study is to estimate the prevalence of OSA and associated metabolic abnormalities in Finnish morbidly obese subjects and to evaluate the effects of bariatric surgery on OSA and associated metabolic abnormalities. The study is conducted in seven hospitals in Finland and 300 patients are planned to be recruited in the study.
Background: Lack of proper stroke care delivery leads to poor patient outcomes in middle- and low-income countries that can be improved by implementation of international standards. We aim to determine feasibility of implementing stroke core measures and training through blended learning modules in resource poor countries to improve stroke outcomes.

Methods: The project will be conducted across four hospitals in Pakistan in three phases. First stage will include retrospective collection of data for the preceding 4 weeks from start. In stage II, 3 months data will be collected before implementation of core measures. The stepwise training of staff will begin simultaneously, and data will continue to be collected. In stage III by the end of 3 months of stage II, core measures will be implemented as standard of care and patients will be enrolled for another 3 months. Outcomes measures will be successful implementation of the stroke care model as measured by survey done at the end and patient outcomes including in-hospital complication rates, length of hospital stay, patient and caregiver education, mRS at 3 months after discharge, post discharge complications and re-stroke rate. Data will be compared against published data from Pakistan and between patients in the first and last 3 months of the project. Statistical analyses will include appropriate mixed-effects multivariate regression models (i.e., linear and logistic) to model the relationship between clinical measures and patient safety. Degree of correlation across each symptom predictor will be measured. This study will not involve thrombolytic therapy or thrombectomy. However, the study will not provide any hindrance to implementation of such therapy and will not include such patients in analysis.

Discussion: At least one third of stroke survivors in Pakistan die due to recurrent vascular events and complications of stroke in absence of core measures. Prevention practices and stroke care are significantly underutilized in low- and middle-income countries but can be improved most efficiently by improving care delivering process without additional burden on resources by following American Heart Association "Get With The Guidelines" Stroke (GWTG-Stroke) program, Royal College of Physicians UK and European Guidelines, regardless of thrombolysis or thrombectomy. This feasibility study aims to develop a multidisciplinary comprehensive stroke team model with gradual integration of staff training, nursing care, therapy and patient education.
INTRODUCTION: Despite adherence to inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy, many patients with asthma experience moderate exacerbations. Data on the impact of moderate exacerbations on the healthcare system are limited. This study assessed the frequency and economic burden of moderate exacerbations in patients receiving ICS/LABA.
METHODS: Retrospective, longitudinal study analyzed data from Optum's de-identified Clinformatics® Data Mart Database recorded between October 1, 2015, and December 31, 2019. Eligibility criteria included patients ≥18 years of age with ≥1 ICS/LABA claim and ≥1 medical claim for asthma in the 12 months pre-index (first ICS/LABA claim). Primary objectives included describing moderate exacerbation frequency, and associated healthcare resource utilization (HRU) and costs. A secondary objective was assessing the relationship between moderate exacerbations and subsequent risk of severe exacerbations. Patients were stratified by moderate exacerbation frequency in the 12 months post index. Moderate exacerbations were identified using a newly developed algorithm.
RESULTS: In the first 12 months post index 61.6% of patients experienced ≥1 moderate exacerbation. Mean number of asthma-related visits was 4.1 per person/year and median total asthma-related costs was $3544. HRU and costs increased with increasing exacerbation frequency. Outpatient and inpatient visits accounted for a similar proportion of these costs. Moderate exacerbations were associated with an increased rate and risk of future severe exacerbations (incidence rate ratio, 1.56; hazard ratio, 1.51 [both p < 0.001]).
CONCLUSIONS: This study highlighted that a high proportion of patients continue to experience moderate exacerbations despite ICS/LABA therapy and subsequently experience increased economic burden and risk of future severe exacerbations.
Methods for producing chewable emulsion compositions and compositions-produced from such methods are disclosed. The emulsion base may be prepared by contacting an aqueous phase and a nonaqueous phase in the presence of an emulsifier. The aqueous phase is prepared under conditions that permit no substantial moisture loss and reduced viscosity. The methods permit preparing chewable compositions for delivering confectionary items, nutriceuticals, vitamins, minerals and therapeutically active agents. The compositions may be sugar-free or sugar-containing. The active agent may be added to the emulsion base at a lower temperature compared to the temperature at which either the aqueous or nonaqueous phase is formed. The compositions may be further coated with taste-masking materials, enteric coating materials, or slow-release materials. The compositions may be formed into compressible tablets, beads, granules, or otherwise generally known dosage forms.
PURPOSE: This study proposes a concept for emotion recognition systems for children with profound intellectual and multiple disabilities (PIMD) based on artificial intelligence (AI) using physiological and motion signals.
METHODS: First, the heartbeat interval (R-R interval, RRI) of a child with PIMD was measured, and the correlation between the RRI and emotion was briefly tested in a preliminary experiment. Then, a concept based on AI for emotion recognition systems for children with PIMD was created using physiological and motion signals, and an emotion recognition system based on the proposed concept was developed using a random forest classifier taking as inputs the RRI, eye gaze, and other data acquired using low physical burden sensors. Subsequently, the developed emotion recognition system was evaluated, validating the proposed concept. Finally, we proposed a validated concept for emotion recognition systems.
RESULTS: A correlation was found between the RRI and emotion. The emotion recognition system was created based on the proposed concept and tested. According to the results, the recognition rate of "negative" and "not negative" of 70.4% ± 6.1% (Mean ± S.D.) of the developed emotion recognition system was higher than 48.5% ± 5.0% of an unfamiliar person used as a control.
CONCLUSION: The results indicate that the proposed concept for emotion recognition systems is useful for communicating with children with PIMD.
YCANTH topical solution is supplied in a sealed glass ampule contained within a single-use applicator and enclosed in a protective paperboard sleeve. Each ampule of YCANTH contains approximately 0.45 mL of 0.7% cantharidin solution. Each mL of YCANTH contains 7 mg cantharidin (0.7%). A YCANTH Break Tool is co-packaged as 2 units per each 6 count and 12 count carton of applicators and 1 unit per each 1 count carton with 1 applicator.

A listing of the available carton packages is provided in Table 3.

Individual YCANTH Break Tools are available separately (Part Reference Number 71349-000-01). 

To request additional YCANTH Break Tools, contact Verrica Pharmaceuticals at 1-973-298-1390.
Two trained dental home visitors made 6-monthly Dental Home Visits (DHVs) to families in the Intervention Group. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion.
Mitral valve repair or replacement surgery. The calculated sample size was 93 patients in the control arm.
The group involved in physiotherapists-led groups was shown the exercises in practice and under the supervision of the physiotherapist, the patients applied their exercises throughout their treatment. Then, all patients were called to the hospital for control after three months and the scale prepared by us and consisting of a total of 5 (five) questions was directed to the patients and it was determined how the exercises given were performed. Five different exercises were given to patients with low back and neck pain who participated in our study. The patients were asked to do these exercises 3 times a day for 10 repetitions. Cat-camel exercises, lumbar stretching, sit-ups, bridge building and back extensor strengthening exercises were given to patients with low back pain. For patients with neck pain, neck flexion-extension, neck lateral flexion, neck rotation, shoulder capsule stretching and shoulder flexion exercises were given.
Sintilimab will be administered as intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase. Sintilimab will be administered as IV infusion 3 weeks during the post-operative adjuvant phase up to 1 year.
The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques.
PCT No. PCT/JP95/04226 Sec. 371 Date Jul. 18, 1997 Sec. 102(e) Date Jul. 18, 1997 PCT Filed Nov. 30, 1995 PCT Pub. No. WO96/16987 PCT Pub. Date Jun. 6, 1997An object of the present invention is to provide a physiologically active substance having activity in acting on the megakaryocyte-platelet system, in promoting the differentiation and maturation of megakaryocytes, and in promoting the formation of platelets. The present invention relates to a thrombocytopoiesis stimulating factor, characterized in having the following amino acid sequence in its molecule, and to a medicinal composition for treating thrombocytopenia, characterized in containing thrombocytopoiesis stimulating factor as an active component: Xaa Gly Asn Asn Asp Glu Ser Asn Ile Ser Phe Lys Glu Lys Asp Ile (where Xaa indicates that the amino acid is unspecified). The physiologically active substance is useful as an active component or the like in therapeutics and preventives for thrombocytopenia and thrombocytopenic purpura associated with chemotherapy and marrow grafts, and for various other diseases which are prone to bleeding attributed to thrombocytopenia.
Clinical studies of verapamil hydrochloride extended-release capsules (PM) were not adequate to determine if subjects aged 65 or over respond differently from younger patients. Other reported clinical experience has not identified differences in response between the elderly and younger patients; however, greater sensitivity to verapamil hydrochloride extended-release capsules (PM) by some older individuals cannot be ruled out.

Aging may affect the pharmacokinetics of verapamil. Elimination half-life may be prolonged in the elderly [see Clinical Pharmacology (12.3)].

Verapamil is highly metabolized by the liver, and about 70% of the administered dose is excreted as metabolites in the urine. Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal impairment, should be considered [see Use in Specific Populations (8.6, 8.7)]. In general, lower initial doses of verapamil hydrochloride extended-release capsules (PM) may be warranted in the elderly [see Dosage and Administration (2.1)].